The Intellectual Property and Science business of Thomson Reuters has announced Cortellis Clinical Trials Intelligence, its global clinical-drug-trial intelligence database, marked an industry-first milestone with the documentation of more than 180,000 clinical trials, thus providing pharmaceutical professionals with greater and quicker access to critical data and strategic insights to build stronger, more effective clinical trials. The solution - launched in August 2013 - is part of the Cortellis suite, the premier source of life sciences intelligence information and analytics across multiple disciplines including regulatory, business development, discovery and pre-clinical.
Thomson Reuters Cortellis Clinical Trials Intelligence provides life science professionals access to information and analytics from more than 180,000 global clinical trials, including coverage of drugs, biologics, diagnostics, biomarkers and medical devices, supporting unparalleled outcome searching. Cortellis users can gain deeper scientific and competitive insights by connecting clinical trial data with drug pipelines, patents, pre-clinical insights and biomarkers on a single, unified platform, reducing time spent compiling and analysing clinical information, and to ultimately construct better trials. The information can also be accessed through APIs embedded in a customer's existing workflow or third party software applications.
Cortellis Clinical Trials Intelligence makes program planning and competitive research simpler and more efficient as the number of clinical trials in the database continues to grow. The solution also allows users to discover competitor strategies for specific patient segments, biomarker utilisation, end points and novel insights into disease processes and to uncover vital connections by integrating their internal, proprietary data with the wide variety of reference information available through Cortellis.
